首页|Generalizing the Intention-to-Treat Effect of an Active Control from Historical Placebo-Controlled Trials: A Case Study of the Efficacy of Daily Oral TDF/FTC in the HPTN 084 Study

Generalizing the Intention-to-Treat Effect of an Active Control from Historical Placebo-Controlled Trials: A Case Study of the Efficacy of Daily Oral TDF/FTC in the HPTN 084 Study

扫码查看
原文链接
  • NETL
  • NSTL
  • Taylor & Francis
In many clinical settings, an active-controlled trial design (e.g., a non-inferiority or superiority design) is often used to compare an experimental medicine to an active control (e.g., an FDA-approved, standard therapy). One prominent example is a recent phase 3 efficacy trial, HIV Prevention Trials Network Study 084 (HPTN 084), comparing long-acting cabotegravir, a new HIV pre-exposure prophylaxis (PrEP) agent, to the FDA-approved daily oral tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) in a population of heterosexual women in 7 African countries. One key complication of interpreting study results in an active-controlled trial like HPTN 084 is that the placebo arm is not present and the efficacy of the active control (and hence the experimental drug) compared to the placebo can only be inferred by leveraging other data sources. In this article, we study statistical inference for the intention-to-treat (ITT) effect of the active control using relevant historical placebo-controlled trials data under the potential outcomes (PO) framework. We highlight the role of adherence and unmeasured confounding, discuss in detail identification assumptions and two modes of inference (point vs. partial identification), propose estimators under identification assumptions permitting point identification, and lay out sensitivity analyses needed to relax identification assumptions. We applied our framework to estimating the intention-to-treat effect of daily oral TDF/FTC versus placebo in HPTN 084 using data from an earlier Phase 3, placebo-controlled trial of daily oral TDF/FTC (Partners PrEP). Supplementary materials for this article are available online, including a standardized description of the materials available for reproducing the work.

Active-controlled trialComplianceGeneralizabilityHIV preventionIntention-to-treat effectPost-randomization event

Qijia He、Fei Gao、Oliver Dukes、Sinead Delany-Moretlwe、Bo Zhang

展开 >

Department of Statistics, University of Washington, Seattle, WA

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA

Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium

Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa

展开 >

2024

10.1080/01621459.2024.2360643

Journal of the American statistical association

Journal of the American statistical association

SCI
ISSN：0162-1459
年,卷(期)：2024.119(548)
  • 49